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Review
Plasmodium vivax Controlled
Human Malaria Infection –
Progress and Prospects
Ruth O. Payne,1,2,* Paul M. Grifﬁn,3,4,5,6 James S. McCarthy,3,6
and Simon J. Draper1,*
Modern controlled human malaria infection (CHMI) clinical trials have almost
entirely focussed on Plasmodium falciparum, providing a highly informative
means to investigate host–pathogen interactions as well as assess potential
new prophylactic and therapeutic interventions. However, in recent years, there
has been renewed interest in Plasmodium vivax, with CHMI models developed
by groups in Colombia, the USA, and Australia. This review summarizes the
published experiences, and examines the advantages and disadvantages of the
different models that initiate infection either by mosquito bite or using a blood-
stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a
platform for early proof-of-concept testing of drugs and vaccines, accelerating
the development of novel interventions.
Controlled Human Malaria Infection
CHMI with Plasmodium falciparum is an established method for evaluating new candidate
vaccines and antimalarial drugs in early-phase proof-of-concept clinical trials. The controlled
nature of these studies enables trials to be undertaken with small numbers of volunteers with
power to investigate efﬁcacy against malaria using a variety of deﬁned end-points, thereby
accelerating development of antimalarial drugs [1,2] and vaccines [3]. CHMI can be initiated by
the traditional mosquito-bite method (still frequently used), by the injection of cryopreserved
sporozoites, or by an inoculum of blood-stage parasites, so-called induced blood stage malaria
(IBSM) [3–10]. P. falciparum strains other than the reference clone 3D7 and its parental strain
NF54 are now being tested, including the 7G8 laboratory isolate and the Cambodian clone
NF135.C10 [11,12]. Genetically attenuated parasites that arrest development during the liver
stage of infection have now been tested in humans [13]. Most of these studies have been carried
out in nonendemic settings, but more recently they have also taken place in endemic countries,
in particular through the use of cryopreserved sporozoites [14,15].
By contrast, modern CHMI with Plasmodium vivax has been less utilized, with only a small
handful of studies reported in the last few years. In only two of the studies published to date has
efﬁcacy of immunization been assessed (Table 1).
There is an extensive history of deliberate infection with P. vivax – most notably in malariotherapy,
which was carried out for the treatment of neurosyphilis almost a century ago. The Austrian
psychiatrist Julius Wagner-Jauregg later received a Nobel Prize for his work with this treatment
[16], and the practice was widely adopted as the only effective treatment available at the time.
Malariotherapy provided a wealth of information about P. vivax infection, which has been
reviewed previously [17]. Deliberate infection with P. vivax was also conducted in the USA
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from the 1940s to the 1970s in prisoners involved in the Malaria Research Project at the Illinois
State Penitentiary. The studies mainly examined compounds for their potential use as antima-
larials [18]. Similar studies were also carried out at the United States Penitentiary, Atlanta, and in
both programs the Chesson strain of malaria was used because it was noted to be more likely to
relapse and have a shorter latency period than previously utilized strains, meaning that com-
pounds could be assessed more rapidly [18,19]. Key discoveries of the biology of P. vivax were
made during this period including, for example, the association between Duffy negativity and
resistance to P. vivax infection [20]. This review focuses on the more recent trials using P. vivax
CHMI rather than these early studies and treatment programs.
P. vivax Studies Using Sporozoite (Mosquito-Bite) CHMI
Following on from the studies of P. vivax infection conducted in Illinois, CHMI experiments were
carried out to see if prior exposure to irradiated mosquitoes could confer protection by
immunization. Rieckmann et al. [21] reported no protection against CHMI in three participants
previously exposed to P. vivax-infected irradiated mosquitoes on four occasions at intervals of
2–4 weeks (total of <200 mosquitoes).
Three P. vivax CHMI studies assessing the ability to ‘immunize’ with X-irradiated sporozoites also
took place in Maryland, USA, during the 1970s. Following immunization, challenge infection was
initiated by periodic exposure to the bites of nonirradiated infected mosquitoes in three
volunteers in separate experiments, and blood ﬁlms were taken at least daily for all volunteers
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Table 1. Overview of Published Plasmodium vivax CHMI Studies
Trial site Number of volunteers Pre-patent
period (days)a
Number of
infected mosquitoes
OR infective inoculum
Number of volunteers
with patent parasitemia
Refs
Sporozoite (mosquito-bite) CHMI studies
Cali,
Columbia
18 9–13 2–10 17/18b [26]
Cali,
Columbia
17 Duffy positive
5 Duffy negative
9–16 2–4 17/17 (Duffy positive)
0/5 (Duffy negative)
[27]
Cali,
Columbia
7 malaria-naïve
9 semi-immune
11–13 2–4 16/16c [28]
Cali,
Columbia
12 Duffy
-positive vaccinees
2 Duffy-positive
controls
5 Duffy-negative
controls
12–13 2–4 7/12 vaccinees
2/2 Duffy-positive
controls
0/5 Duffy-negative
controls
[31]
WRAIR,
USA
27 vaccinees
6 infectivity controls
10–13
10–11
5 27/27 vaccinees
6/6 controls
[32]
Blood-stage CHMI studies (IBSM)
QIMRB,
Australia
2 8–9 13 000 genome
equivalents
2/2 [35]
QIMRB,
Australia
6 8–9 31 786 ( 11 947) as
determined by qPCR
(= 15  5 viable
P. vivax parasites)
6/6 [37]
aThe pre-patent period refers to the period before malaria diagnosis which was made by blood ﬁlm in sporozoite (mosquito-
bite) studies and qPCR in the blood-stage studies.
bOne volunteer did not develop parasitemia; the authors of the study suggested that this may have been due to surreptitious
self-administration of antimalarial medication, but this was not proven.
cOne volunteer developed parasitemia detectable by qPCR but cleared it spontaneously within 4 days.
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to assess outcome; between 6 and 14 infected nonirradiated mosquitoes were used for the
infection challenges. These experiments in Maryland demonstrated that CHMI with both
P. falciparum and P. vivax could be successfully carried out, but the studies were very small.
In these studies, exposure to P. falciparum did not confer protection against subsequent CHMI
with Chesson strain P. vivax [22,23]. However, exposure to X-irradiated Chesson strain and El
Savador strain P. vivax was able to confer protection against P. vivax CHMI following some of the
‘immunization phases’, but not all [22–24]. It was also noted that, unlike the Chesson strain, the
newly isolated El Salvador P. vivax strain demonstrated long latency. In summary, the pre-patent
period (time before development of blood ﬁlm-detectable parasitemia) for control volunteers in
the three experiments ranged between 9 and 16 days. These experiments also demonstrated
that protection against P. vivax infection could be achieved for a short duration (3–5 months), but
required exposure to hundreds of X-irradiated mosquitoes. Recent data emerging from the ﬁeld
of P. falciparum sporozoite immunization indicate that the magnitude of protection, longevity of
protection, and the ability to protect against heterologous strains requires increasing doses of
sporozoites [25]. Future CHMI studies with P. falciparum and P. vivax may build on these
historical experiments to assess whether the same is true for P. vivax and even cross-species
protection.
More recent mosquito-bite CHMI trials have taken place in Cali, Colombia. The ﬁrst of these
involved 18 healthy volunteers exposed to the bites of two to ten infected Anopheles albimanus
mosquitoes [26]. P. vivax infection was established in mosquito lots fed on blood from 15
patients presenting to outpatient clinics at the Immunology Institute in Cali and Buenaventura
with P. vivax infection. Four mosquito lots had to be discarded due to coinfection with
P. falciparum, hepatitis B, or hepatitis C in the donor blood. A mosquito lot that demonstrated
a sporozoite rate of 97% the day before CHMI was selected for use in the trial. Seventeen of the
18 volunteers developed P. vivax malaria, conﬁrmed by thick blood smear, with a pre-patent
period between 9 and 13 days. At diagnosis, volunteers were treated with standard P. vivax
therapy consisting of chloroquine (600 mg initially, followed by 450 mg 24 and 48 h later) to clear
blood-stage infection and primaquine (30 mg/day for 14 days) to achieve radical cure. Levels of
parasitemia ranged from 75 to 420 parasites/mL; parasites were cleared within 48 h of starting
treatment in all infected volunteers. There were no serious adverse events (SAEs) in this trial, but
seven volunteers required ﬂuid therapy due to nausea and vomiting, and ﬁve developed blurred
vision lasting 2–3 days after treatment initiation. Authors speculated that the volunteer who did not
develop malaria had surreptitiously taken antimalarial medication, but this was never conﬁrmed.
The second P. vivax CHMI trial was carried out by the same group in Colombia, aiming to
demonstrate the reproducibility of this method of infection using three different A. albimanus
mosquito lots fed on blood from three P. vivax-infected donors [27]. Seventeen Duffy-positive
individuals and ﬁve Duffy-negative controls were enrolled into the study. Participants were
randomly assigned to three groups (with six Duffy-positive individuals in two of the groups
and ﬁve in the third group), and exposed to the bites of two to four infected mosquitoes. The
Duffy-negative controls were assigned across the three groups, with two controls in the ﬁrst two
groups and one in the third. All Duffy-positive participants (and none of the Duffy-negative
participants) developed blood-stage malaria. The pre-patent period ranged from 9 to 16 days,
and was different in the ﬁrst group, with a median of 14 days, as opposed to a median of 10 days
in the second two groups.
A third P. vivax CHMI trial was carried out in Cali but this time among both ‘semi-immune’
(previously-exposed; n = 9) and malaria-naïve adult volunteers (n = 7) [28]. Previous exposure
was conﬁrmed by clinical history and a positive indirect ﬂuorescent antibody test against P. vivax
blood stages. A mosquito lot from one of six P. vivax-infected patients was used for all volunteers,
who were each exposed to bites from two to four infected mosquitoes. The pre-patent periods
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ranged between 11 and 13 days, with no signiﬁcant difference between the malaria-naïve and
‘semi-immune’ volunteers. Symptoms were signiﬁcantly worse among the malaria-naïve subjects
but there were no SAEs. One malaria-naïve volunteer developed parasitemia detectable by real-
time quantitative polymerase chain reaction (RT-qPCR) by day 9, but cleared the parasitemia
spontaneously in 4 days. An antimalarial drug screen was negative; the authors speculated that
this phenomenon may be due to Duffy antigen polymorphism. Another malaria-naïve volunteer
presented 3 months after treatment with a P. vivax infection after visiting an endemic area.
However, the investigators were unable to determine whether this episode of malaria was due to
reinfection or relapse, as the volunteer had visited the same endemic area that the CHMI strain
had come from.
A subsequent analysis of differences in gene expression between malaria-naïve and ‘semi-
immune’ volunteers demonstrated signiﬁcant changes in gene expression at the time of malaria
diagnosis, particularly in the naïve volunteers, with downregulation of multiple genes related to
innate immunity, inﬂammation, and neutrophil abundance [29]. Antibody proﬁling was also
undertaken, using a custom protein microarray. This demonstrated increased responses in
the semi-immune participants compared with naïve individuals before CHMI, although
responses in both groups were higher than those from US controls. Following CHMI, antibody
responses increased on day 45 and had declined to near baseline by day 145. Volunteers who
experienced fever were found to have signiﬁcantly higher responses to the P. vivax antigens
merozoite surface protein 3 (MSP3), MSP4, MSP5, and MSP10 at the day 45 time-point [30].
The most recent CHMI trial from the Cali group [31] involved the use of radiation-attenuated
sporozoites in Duffy-positive and Duffy-negative healthy adult volunteers, delivered by mosquito
bite. Mosquitoes were infected as described above for the other trials conducted by this group.
Sporozoites were attenuated by exposing the mosquitoes to 150  10 cGy of gamma irradia-
tion. Twelve Duffy-positive participants and ﬁve Duffy-negative controls completed the immuni-
zation phase with exposure to P. vivax-infected irradiated A. albimanus mosquitoes followed by
CHMI. Two Duffy-positive controls also completed the trial; these participants were exposed to
nonirradiated, noninfected mosquitoes. Seven immunizations were carried out for each volun-
teer on weeks 0, 8, 12, 23, 48, 51, and 56, with a mean of 65 infectious bites for each
immunization. Two weeks after the ﬁnal immunization, participants were treated with chloro-
quine and primaquine to clear any malaria infections that may have developed during the
immunization phase. Plasma levels of chloroquine and primaquine were checked prior to CHMI
to ensure drug clearance. CHMI was carried out at week 64 using two to four P. vivax-infected
mosquito bites, and participants were monitored daily with thick blood ﬁlms from day 6. There
were no reported SAEs related to immunization, although one volunteer developed severe
elevation of hepatic transaminases [>10 times the upper limit of normal (x ULN)] with associated
abdominal pain and vomiting following CHMI, with no alternative cause found. These symptoms
resolved spontaneously. The protective efﬁcacy of the immunization schedule was 42% (ﬁve out
of twelve Duffy-positive participants protected). In volunteers who developed malaria, the mean
pre-patent period until thick blood ﬁlm positivity was 12.8 days. Interestingly, all of the volunteers
protected in this trial were female [31].
Only one other CHMI trial assessing a P. vivax vaccine has been published to date. The VMP001/
AS01B vaccine was tested in healthy malaria-naïve adults at the Walter Reed Army Institute of
Research (WRAIR) in the USA [32]. VMP001 is a soluble recombinant protein vaccine [33],
encoding the P. vivax circumsporozoite protein (PvCSP), administered with the AS01B adjuvant
(GlaxoSmithKline). The vaccine was administered to 30 volunteers in three cohorts (10 in each) at
doses of 15 mg, 30 mg, and 60 mg, given three times at a 4-week interval between the ﬁrst and
second dose; the third dose was given 8 (15 mg cohort), 6 (30 mg cohort), or 4 (60 mg cohort)
weeks after the second. Twenty-nine volunteers completed the vaccination phase, with
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27 proceeding to CHMI 2 weeks after ﬁnal vaccination, along with six malaria-naïve controls.
Mosquito-bite CHMI with ﬁve P. vivax-infected Anopheles dirus mosquitoes was undertaken.
Laboratory-reared mosquitoes were fed on blood from a P. vivax-infected donor in Thailand after
screening by PCR to ensure no coinfection with other Plasmodium species or blood-borne
infections. Infected mosquitoes were then transported to WRAIR and maintained in their
insectary until CHMI. Volunteers were treated following a diagnosis of vivax malaria by thick
blood smear. The vaccine protective efﬁcacy was 0%; all volunteers had developed thick blood
ﬁlm-detectable parasitemia by day 13. The median pre-patent period for all immunized partic-
ipants was 11.9 days versus 10.7 days for infectivity controls. Participants were treated with
standard chloroquine and primaquine therapy with rapid clearance of infection. However, two
volunteers went on to have multiple relapses. One participant experienced two relapses (at
weeks 8 and 18 after CHMI), while the other experienced three (at weeks 11, 20, and 48 after
CHMI) [34]. By study completion, the participants had been followed up for 5 years, and had not
had any further relapses [32]. Exploratory genotyping for the cytochrome P450 (CYP) allele
CYP2D6 was undertaken in 25 of the 33 volunteers. The volunteers with relapses were found to
have either an intermediate-metabolizer phenotype or poor-metabolizer phenotype. These
phenotypes were associated with signiﬁcantly lower levels of primaquine clearance 24 h after
dosing [34]. Primaquine is metabolized into redox-active metabolites by CYP2D6, and therefore
individuals who are unable to metabolize the drug in sufﬁcient quantities appear to be at risk of
relapse from P. vivax.
Another CSP P. vivax vaccine (CS long synthetic peptides formulated in Montanide ISA 51) is
currently being assessed in a mosquito-bite CHMI trial (NCT02083068), but no results have yet
been published.
Studies Using Blood-Stage CHMI
There have been four P. vivax IBSM/blood-stage CHMI studies to date successfully carried out
at QIMR Berghofer in Brisbane, Australia, two of which have been published. The ﬁrst trial was a
proof-of-concept study with only two volunteers, using an inoculum collected from a donor
whose blood group was A, Rh negative, Duffy-positive who had travelled to the Solomon Islands
and returned with clinical vivax malaria, designated HMPBS01-Pv [35]. This demonstrated that
infection with P. vivax malaria could successfully be achieved from a frozen inoculum, as has
been demonstrated with P. falciparum for many years [5,6]. The two volunteers were injected
intravenously with around 13 000 genome equivalents of P. vivax and developed parasitemia
detectable by qPCR on days 8–9, with a peak parasitemia on the day of treatment (day 14) in
both individuals. In this case, the challenge inoculum cannot be cultured by limiting dilution to
determine the parasite dose (as is routinely done for P. falciparum) [7,36], and hence a qPCR-
based method was used to quantify the inoculum. Both subjects developed symptoms
consistent with early malaria infection. Volunteers were treated with a standard treatment course
of artemether–lumefantrine (four tablets each containing 20 mg artemether and 120 mg lume-
fantrine every 12 h for six doses), with a subsequent rapid decline in parasitemia. Of note, the
presence of a marker of mature gametocytes was detectable in the blood of both volunteers by
qPCR on days 11–12, prior to the onset of symptoms in one volunteer. In this case the
gametocyte marker was pvs25 transcripts – these are expressed by the parasite shortly before
gametocyte fertilization with synthesis peaking over the proceeding hours.
The second study utilized the same inoculum in a further six subjects and was designed to
validate the pilot study model and evaluate the potential for transmission to vector mosquitoes
[37]. The mean dose of parasites ( SD) administered to the six subjects in this study was 31 786
( 11 947) parasites as determined by qPCR testing of the inoculum, whilst linear regression
modelling of the in vivo qPCR parasite growth data estimated the starting dose of viable
parasites to be a mean  SEM of 15  5 parasites. The kinetics of the parasitemia (determined
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by qPCR) were similar in all volunteers with ﬁrst detection on day 8 in four subjects and day 9 in
two subjects. Peak parasitemia occurred on day 14 (the day of antimalarial treatment) with a
median of 31 parasites/mL. The parasite multiplication rate (PMR), assuming a 48-hour lifecycle,
was 9.9 (95% CI: 7.7–12.4). The clinical course was also similar in all volunteers, with the mean
onset of symptoms occurring on day 12.2 (range 11–13).
There were no SAEs reported in this study; most of the adverse events were mild expected
symptoms of malaria. However, four of the six subjects demonstrated signiﬁcant elevations of
hepatocellular enzymes (>5 x ULN), although asymptomatic and not associated with signiﬁcant
elevations in bilirubin (Hy's law was not met) (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf). The speciﬁc cause
of the elevated hepatocellular enzymes was not conclusively determined, but extensive addi-
tional investigations, including viral serologies (hepatitis viruses, herpes viruses, alphaviruses and
ﬂaviviruses), other biomarkers (creatinine kinase, paracetamol levels), and liver ultrasound did not
demonstrate any signiﬁcant abnormalities. The inoculum (and donor) had been screened to
exclude the presence of blood-borne pathogens other than malaria to a greater level than
required by the local blood service. All subjects were treated with artemether–lumefantrine on
study day 14 with a corresponding rapid decline in parasitemia and clinical symptoms.
There was no evidence of reactions to the donor's blood, that is, no transfusion reactions and no
red cell alloantibodies detected, and no evidence of transmitted infection (other than malaria).
Whilst the initial P. vivax isolate demonstrated a favourable proﬁle in two studies, it was obtained
from a blood group A donor. Therefore, to reduce the probability of alloantibody generation and
to optimize the probability of infection, it is required that recipients are also blood group A (and
Duffy positive). This signiﬁcantly limits the number of eligible volunteers. To overcome this
limitation, and as a result of an ongoing cryobanking project, a second P. vivax isolate was
obtained from a blood group O patient who returned to Brisbane, Australia, having acquired
P. vivax infection in India. This inoculum has since been used in two further studies
(ACTRN12614000930684 and ACTRN12616000174482), but results have not yet been
published.
The development of gametocytemia in volunteers undergoing CHMI has implications for carrying
out such studies in areas of the world where Anopheles mosquito vectors are present and
capable of supporting transmission. Of note, A. albimanus mosquitoes fed on blood from
infected volunteers between day 7 post-CHMI and the day of diagnosis (days 11–13) in the third
trial carried out in Cali, Columbia [28], did not develop oocysts over the next 7 days. This was
despite the presence of parasites, likely to be gametocytes, being identiﬁed in the circulation as
early as day 7 by qPCR for two sexual stage-speciﬁc molecular markers, pvs25 and pvs16.
Direct (skin) feeding was carried out as well as via a membrane feeding assay. In contrast,
parasites obtained from submicroscopic asymptomatic and naturally infected individuals were
able to infect mosquitoes [38]. This difference is thought to be due to insufﬁcient maturation of
gametocytes at the point of diagnosis in the early CHMI infections.
The second blood-stage CHMI trial in Brisbane showed more promise for assessment of
transmission [37]. In this trial, detection of pvs25 transcripts was used as a marker of game-
tocytemia. Expected kinetics relative to the parasitemia were observed, with peak pvs25
detection occurring immediately prior to antimalarial treatment (day 14), with a median of
4.90  105 transcripts/mL (range from 3.96  104 to 2.37  106). The potential for transmission
to mosquito vectors was assessed by direct (skin) and membrane mosquito feeding for 2 to 3
days prior to antimalarial therapy. A total of 16 direct feeding assays and 32 membrane feeding
assays were conducted. A total of 1801 Anopheles stephensi mosquitoes were dissected
for the detection of oocysts, and a low prevalence of mosquito infection was observed
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(1.8%; n = 32/1801 mosquitos). Moreover, unlike P. falciparum, P. vivax gametocytes are
susceptible to asexual-stage antimalarial treatment so any gametocytes should also be cleared
following initiation of standard therapy [39].
In line with these experiences, a recently developed simulation model (using data from a
previously developed model of red blood cell invasion and information from six published time
series of parasitemia from neurosyphilis patients treated with P. vivax) further supports these
ﬁndings. Data suggest that a density of 116 gametocytes/mL is required for there to be at least
one male and one female gametocyte in a 1 mL blood meal, and this model predicts that this
threshold will ﬁrst be reached in an infected naïve host at 7.9 days post patency on average (95%
CI 5–10) [40]. Overall, these data suggest that transmission efﬁciency during standard CHMI
protocols would likely be very low.
Comparison of CHMI Models
Modern CHMI studies have proved extremely useful in early-phase testing of P. falciparum
vaccines [3,6,41–46] and drugs [1,2,47,48]. The development of modern CHMI approaches for
P. vivax is less well established, but has the potential to provide a useful and cost-effective
means of early-phase analysis of antimalarial drugs and vaccines. To date, the only methods
trialled in humans are CHMI by mosquito bite or by intravenous inoculation of parasitized red
blood cells. Cryopreserved sporozoites, as developed by Sanaria, are another potential method
for CHMI, but unlike P. falciparum cryopreserved sporozoites (PfSPZ Challenge), have not yet
been used in any human trials (http://projectreporter.nih.gov/project_info_description.cfm?aid=
8446961).
There are advantages and limitations to both available CHMI models (see Outstanding Ques-
tions). Mosquito-bite CHMI most closely resembles natural infection but requires fresh game-
tocytes from an infected patient due to the unavailability of long-term P. vivax culture. This
requires at least part of the trial to be undertaken in an endemic setting to screen and enrol
patients, with appropriate entomological facilities established to produce an infected mosquito
lot. Subsequently, the mosquito lot can be used in trials in the same location, or transported to
nonendemic areas. Ensuring the successful production of infected mosquitoes, in conjunction
with recruitment of volunteers who may receive an intervention such as a vaccine, poses
signiﬁcant logistical challenges, especially if the timing of the vaccination and subsequent CHMI
are critical. Moreover, a different isolate of P. vivax will inevitably be used for every trial, meaning
that CHMI assessment of vaccines is almost certainly to be with a heterologous strain to that
used in the vaccine; that the parasites may have different susceptibility to antimalarial treatment
between strains; and these differences will be unknown at the time of CHMI. As seen in the trials
carried out in Cali, different strains are likely to have different pre-patent periods which can limit
comparability between trials [27]. The use of sporozoites for CHMI also necessitates a liver stage
of infection, with a high risk of hypnozoite formation and potential relapse. This requires
participants to be screened for glucose-6-phosphate dehydrogenase (G6PD) deﬁciency in
order to avoid hemolysis induced by primaquine, and now also requires assessment of the
volunteers’ ability to metabolize primaquine to maximize safety. Volunteers with poor or inter-
mediate metabolizer CYP2D6 phenotypes should not be enrolled for such studies in the future.
The use of IBSM/blood-stage CHMI does not mimic natural infection but has several advantages
over mosquito-bite CHMI. Practical advantages include the ability to carry out CHMI studies
more easily in a nonendemic setting; having access to the P. vivax strain genetic data before
CHMI; being able to carry out multiple studies with the same strain (for which a safety database
can be established); and being able to use the same inoculum size for each volunteer or even
vary the dose of parasites administered if required. There are also advantages for participants
with this method – the use of blood-stage parasites means that there is no liver stage of infection,
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and therefore no risk of hypnozoite formation or relapse. This means that participants do not
require primaquine treatment, and therefore do not require G6PD deﬁciency or CYP2D6
phenotype screening. Although the numbers of participants who have undergone this method
of CHMI are still currently very small, all have successfully been infected with an expected rise in
parasitemia detected by qPCR multiplication, unlike in two of the ﬁve reported mosquito-bite
CHMI studies. The ability to give a small known inoculum directly into the bloodstream also
means that the blood stage of infection can be observed for longer (than following mosquito-bite
CHMI), and differences in PMR are more likely to be observed between participants and
controls. A recent blood-stage P. falciparum CHMI trial in Oxford has demonstrated greater
power to see a reduction in PMR with smaller numbers of volunteers as compared with
sporozoite CHMI studies [36]. Blood-stage CHMI is thus particularly advantageous for the
assessment of antimalarial drugs and vaccines which target the erythrocytic stage of the malaria
parasite. The model is of course unable to be used for assessment of pre-erythrocytic inter-
ventions which does limit its utility, and whether either model can be optimized to robustly assess
transmission-blocking interventions remains to be determined.
Concluding Remarks and Future Perspectives
The development of CHMI models for P. vivax is a vital step towards early-phase vaccine and drug
testing, allowing relatively small and inexpensive Phase II efﬁcacy trials to take place before larger
ﬁeld trials. The use of P. vivax CHMI is more complex than the now established P. falciparum
models because of inherent differences between the parasites’ biology and, in particular, the
inability to maintain P. vivax in long-term culture. Mosquito-bite CHMI currently requires access to
infected patients and entomology facilities, and leads to the use of genetically variable isolates in
each study. The use of cryopreserved sporozoites in the future may represent a particularly useful
advancement, but this approach has yet to reach clinical testing. Other approaches may include
the use of P. falciparum parasites transgenic for antigens of interest to allow for easier CHMI
assessment of sporozoite or liver-stage vaccine candidates. To date only one clinical study has
been reported using a genetically modiﬁed P. falciparum parasite, in this case a knockout parasite
line [13]. Transgenic parasites have been developed for use in preclinical and in vitro studies
against P. vivax, so there is potential for development for clinical use [49,50].
Blood-stage P. vivax CHMI remains in its infancy, but will likely be more widely used for novel
vaccine and drug testing in the coming years. To date, only one vaccine targeting the P. vivax
blood-stage merozoite – using the chimpanzee adenovirus serotype 63 (ChAd63) and modiﬁed
vaccinia virus Ankara (MVA) viral vectors encoding the P. vivax Duffy-binding protein region II
(PvDBP_RII) in a heterologous prime-boost regimen [51] – has completed Phase Ia clinical
testing in the UK (NCT01816113) and could progress to Phase IIa efﬁcacy testing. A second
protein-based PvDBP_RII vaccine formulated in SE-GLA adjuvant has recently entered Phase I
clinical trial in India (CTRI/2016/09/007289). The demonstration of a blood-stage CHMI model
for vaccine testing, using P. falciparum [36], should allow for similar advances with P. vivax in the
future. This model may also allow for studies of naturally acquired P. vivax immunity if trial centres
are established in endemic areas, as is starting to occur now for P. falciparum in Africa [14,15].
The development of multiple banks of cryopreserved strains will also allow for vaccine testing
against homologous and heterologous strains potentially originating from different geographic
areas. CHMI trials can also be used to further investigate the mechanism, immunity, and host–
pathogen interactions under controlled infection conditions in humans – the ultimate animal
model. These endeavours should help to provide essential new tools to aid in the ﬁght against
P. vivax, as efforts continue to move towards local malaria elimination.
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Outstanding Questions
Can P. vivax CHMI models be devel-
oped to allow for robust testing of
blood-stage vaccines and transmis-
sion-blocking interventions?
Can a bank of different blood-stage P.
vivax isolates be established to allow
for routine CHMI/IBSM studies using
deﬁned, but genetically heteroge-
neous, parasites?
Can cryopreserved P. vivax sporo-
zoites be established to initiate CHMI,
potentially using an isolate that mini-
mizes risk of relapsing infection?
What efﬁcacy outcome measures fol-
lowing CHMI would be sufﬁcient, for
different types of intervention, to war-
rant further clinical development and/or
testing in the ﬁeld?
Can P. vivax CHMI in naturally immune
or endemic populations provide
greater insight into mechanisms of
immunity to this parasite?
Can screening for volunteers’ cyto-
chrome P450 isoenzyme (CYP2D6)
genotype/phenotype identify those
more likely to fail primaquine therapy
and prevent relapse following P. vivax
sporozoite CHMI?
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